This study evaluated the use of novel peptides derived from platelet-derived growth factor (PDGF-BB) as potential wound healing stimulants. One of the compounds (named PDGF2) was subjected for further research after cytotoxicity and proliferation assays on human skin cells. Further investigation included evaluation of: migration and chemotaxis of skin cells, immunological and allergic safety, the transcriptional analyses of adipose-derived stem cells (ASCs) and dermal fibroblasts stimulated with PDGF2, and the use of dorsal skin wound injury model to evaluate the effect of wound healing in mice.
Approach:
Colorimetric lactate dehydrogenase and tetrazolium assays were used to evaluate the cytotoxicity and the effect on proliferation. PDGF2 effect on migration and chemotaxis was also checked. Immunological safety and allergic potential were evaluated with a lymphocyte activation and basophil activation test. Transcriptional profiles of ASCs and primary fibroblasts were assessed after stimulation with PDGF2. Eight-week-old BALB/c female mice were used for dorsal skin wound injury model.
Results:
PDGF2 showed low cytotoxicity, pro-proliferative effects on human skin cells, high immunological safety, and accelerated wound healing in mouse model. Furthermore, transcriptomic analysis of ASCs and fibroblasts revealed the activation of processes involved in wound healing and indicated its safety.
Innovation:
A novel peptide derived from PDGF-BB was proved to be safe drug candidate in wound healing. We also present a multifaceted in vitro model for the initial screening of new compounds that may be potentially useful in wound healing stimulation.
Conclusion:
The results show that peptide derived from PDGF-BB is a promising drug candidate for wound treatment.
Get full access to this article
View all access options for this article.
References
1.
PikułaM, LangaP, KosikowskaP, TrzonkowskiP. Stem cells and growth factors in wound healing. Postepy Hig Med Dosw, 2015; 69:874–885.
2.
OlczykP, Mencner Ł, Komosinska-VassevK. The role of the extracellular matrix components in cutaneous wound healing. Biomed Res Int, 2014; 2014:747584.
3.
PikułaM, TrzonkowskiP. Biology of epidermal stem cells: impact on medicine. Postepy Hig Med Dosw, 2009; 63:449–456.
4.
Bowen-PopeDF, RainesEW. History of discovery: platelet-derived growth factor. Arterioscler Thromb Vasc Biol, 2011; 31:2397–2401.
5.
WernerS, GroseR. Regulation of wound healing by growth factors and cytokines. Physiol Rev, 2003; 83:835–870.
6.
ChengB, LiuHW, FuXB, SunTZ, ShengZY. Recombinant human platelet-derived growth factor enhanced dermal wound healing by a pathway involving ERK and c-fos in diabetic rats. J Dermatol Sci, 2007; 45:193–201.
7.
BarrientosS, BremH, StojadinovicO, Tomic-CanicM. Clinical application of growth factors and cytokines in wound healing. Wound Repair Regen, 2014; 22:569–578.
8.
BarrientosS, StojadinovicO, GolinkoMS, BremH, Tomic-CanicM. PERSPECTIVE ARTICLE: growth factors and cytokines in wound healing. Wound Repair Regen, 2008; 16:585–601.
9.
ShahP, KepplerL, RutkowskiJ. A review of platelet derived growth factor playing pivotal role in bone regeneration. J Oral Implantol, 2014; 40:330–340.
10.
CapobiancoCM, ZgonisT. An overview of negative pressure wound therapy for the lower extremity. Clin Podiatr Med Surg, 2009; 26:619–631.
11.
HuncklerJ, de MelA. A current affair: electrotherapy in wound healing. J Multidiscip Healthc, 2017; 10:179–194.
12.
SunBK, SiprashviliZ, KhavariPA. Advances in skin grafting and treatment of cutaneous wounds. Science, 2014; 346:941–945.
13.
YuJR, NavarroJ, CoburnJC, et al.Current and future perspectives on skin tissue engineering: key features of biomedical research, translational assessment, and clinical application. Adv Healthc Mater, 2019; 8:e1801471.
KanjiS, DasH. Advances of stem cell therapeutics in cutaneous wound healing and regeneration. Mediators Inflamm, 2017; 2017:5217967.
16.
HirschT, RothoeftT, TeigN, et al.Regeneration of the entire human epidermis by transgenic stem cells. Nature, 2017; 551:327–332.
17.
DuQS, XieNZ, HuangRB. Recent development of peptide drugs and advance on theory and methodology of peptide inhibitor design. Med Chem, 2015; 11:235–247.
18.
TsomaiaN. Peptide therapeutics: targeting the undruggable space. Eur J Med Chem, 2015; 94:459–470.
19.
LiuH, DuanZ, TangJ, LvQ, RongM, LaiR. A short peptide from frog skin accelerates diabetic wound healing. FEBS J, 2014; 281:4633–4643.
20.
Di GraziaA, CappielloF, ImanishiA, et al.The frog skin-derived antimicrobial peptide esculentin-1a(1–21)NH2 promotes the migration of human haCaT keratinocytes in an EGF receptor-dependent manner: a novel promoter of human skin wound healing?. PLoS One, 2015; 10:e0128663.
21.
Jung KimD, LeeYW, ParkMK, et al.Efficacy of the designer antimicrobial peptide SHAP1 in wound healing and wound infection. Amino Acids, 2014; 46:2333–2343.
22.
PickartL, Vasquez-SolteroJM, MargolinaA. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int, 2015; 2015:1–7.
23.
Van KilsdonkJWJ, JansenPAM, Van Den BogaardEH, et al.The effects of human beta-defensins on skin cells in vitro. Dermatology, 2017; 233:155–163.
24.
BanerjeeP, SugunaL, ShanthiC. Wound healing activity of a collagen-derived cryptic peptide. Amino Acids, 2015; 47:317–328.
25.
DeptułaM, WardowskaA, DzierżyńskaM, Rodziewicz-MotowidłoS, PikułaM. Antibacterial peptides in dermatology-strategies for evaluation of allergic potential. Molecules, 2018; 23:414.
26.
Demidova-RiceTN, WolfL, DeckenbackJ, HamblinMR, HermanIM. Human platelet-rich plasma- and extracellular matrix-derived peptides promote impaired cutaneous wound healing in vivo. PLoS One, 2012; 7:e32146.
27.
GomesA, TeixeiraC, FerrazR, et al.Wound-healing peptides for treatment of chronic diabetic foot ulcers and other infected skin injuries. Molecules, 2017; 22:1743.
28.
DeptułaM, ZielińskiJ, WardowskaA, PikułaM. Wound healing complications in oncological patients: perspectives for cellular therapy. Adv Dermatol Allergol, 2019; 36:139–146.
29.
TrostrupH, BjarnsholtT, Kirketerp-MollerK, HoibyN, MoserC. What is new in the understanding of non healing wounds epidemiology, pathophysiology, and therapies. Ulcers, 2013; 2013:1–8.
30.
SchremlS, SzeimiesR-M, PrantlL, LandthalerM, BabilasP. Wound healing in the 21st century. J Am Acad Dermatol, 2010; 63:866–881.
31.
FrykbergRG, BanksJ. Challenges in the treatment of chronic wounds. Adv Wound Care, 2015; 4:560–582.
32.
DreifkeMB, JayasuriyaAA, JayasuriyaAC. Current wound healing procedures and potential care. Mater Sci Eng C Mater Biol Appl, 2015; 48:651–662.
EmingSA, MartinP, Tomic-CanicM. Wound repair and regeneration: mechanisms, signaling, and translation. Sci Transl Med, 2014; 6:265sr6.
35.
MalesevicM, StrijowskiU, BächleD, SewaldN. An improved method for the solution cyclization of peptides under pseudo-high dilution conditions. J Biotechnol, 2004; 112:73–77.
36.
LangaP, WardowskaA, ZielińskiJ, et al.Transcriptional profile of in vitro expanded human epidermal progenitor cells for the treatment of non-healing wounds. J Dermatol Sci, 2018; 89:272–281.
37.
MieczkowskaA, SchumacherA, FilipowiczN, et al.Immunophenotyping and transcriptional profiling of in vitro cultured human adipose tissue derived stem cells. Sci Rep, 2018; 8:11339.
38.
KosikowskaP, PikulaM, LangaP, TrzonkowskiP, ObuchowskiM, LesnerA. Synthesis and evaluation of biological activity of antimicrobial pro-proliferative peptide conjugates. PLoS One, 2015; 10:1–16.
39.
BoukampP, PetrussevskaRT, BreitkreutzD, HornungJ, MarkhamA, FusenigNE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol, 1988; 106:761–771.
40.
BoukampP, PoppS, AltmeyerS, et al.Sustained nontumorigenic phenotype correlates with a largely stable chromosome content during long-term culture of the human keratinocyte line HaCat. Genes Chromosom Cancer, 1997; 19:201–214.
41.
DȩbowskiD, ŁukajtisR, ŁȩgowskaA, et al.Inhibitory and antimicrobial activities of OGTI and HV-BBI peptides, fragments and analogs derived from amphibian skin. Peptides, 2012; 35:276–284.
42.
BonnerJC, Osornio-VargasAR. Differential binding and regulation of platelet-derived growth factor A and B chain isoforms by alpha 2-macroglobulin. J Biol Chem, 1995; 270:16236–16242.
43.
MahadevanD, YuJC, SaldanhaJW, et al.Structural role of extracellular domain 1 of alpha-platelet-derived growth factor (PDGF) receptor for PDGF-AA and PDGF-BB binding. J Biol Chem, 1995; 270:27595–27600.
44.
AnderssonM, OstmanA, KreysingJ, BäckströmG, Van de PollMHC. Involvement of loop 2 of platelet-derived growth factor-AA and -BB in receptor binding. Growth Factors, 1995; 12:159–164.
45.
Hye-Ryong ShimA, LiuH, FociaPJ, ChenX, LinPC, HeX. Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proc Natl Acad Sci U S A, 2010; 107:11307–11312.
46.
OefnerC, D'ArcyA, WinklerFK, EggimannB, HosangM. Crystal structure of human platelet-derived growth factor BB. EMBO J, 1992; 11:3921–3926.
47.
JaumannM, TatjeD, HoppeJ. Identification of individual amino acids in platelet-derived growth factor that contribute to the specificity towards the β-type receptor. FEBS Lett, 1992; 302:265–268.
48.
ClementsJM, BawdenLJ, BloxidgeRE, et al.Two PDGF-B chain residues, arginine 27 and isoleucine 30, mediate receptor binding and activation. EMBO J, 1991; 10:4113–4120.
49.
HeldinCH, LennartssonJ, WestermarkB. Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis. J Intern Med, 2018; 283:16–44.
50.
BrennandDM, DennehyU, EllisV, et al.Identification of a cyclic peptide inhibitor of platelet-derived growth factor-BB receptor-binding and mitogen-induced DNA synthesis in human fibroblasts. FEBS Lett, 1997; 413:70–74.
51.
BrennandDM, ScullyMF, KakkarVV, PatelG. A cyclic peptide analogue of loop III of PDGF-BB causes apoptosis in human fibroblasts. FEBS Lett, 1997; 419:166–170.
52.
PatelG, HusmanW, JehanliAM, et al.A cyclic peptide analogue of the loop III region of platelet-derived growth factor-BB is a synthetic antigen for the native protein. J Pept Res, 1999; 53:68–74.
53.
MerzoukA, SalariH, ArabL, et al.C-terminal cyclization of an SDF-1 small peptide analogue dramatically increases receptor affinity and activation of the CXCR4 receptor. J Med Chem, 2002; 45:2024–2031.
54.
YapBK, LeungEWW, YagiH, et al.A potent cyclic peptide targeting SPSB2 protein as a potential anti-infective agent. J Med Chem, 2014; 57:7006–7015.
55.
NguyenLT, ChauJK, PerryNA, de BoerL, ZaatSAJ, VogelHJ. Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. PLoS One, 2010; 5:e12648
56.
KukowskaM, PikułaM, Kukowska-KaszubaM, SchumacherA, DzierzbickaK, TrzonkowskiP. Synthetic lipopeptides as potential topical therapeutics in wound and skin care: in vitro studies of permeation and skin cells behaviour. RSC Adv, 2016; 6:115120–115131.
57.
ZbytekB, PikulaM, SlominskiRM, et al.Corticotropin-releasing hormone triggers differentiation in HaCaT keratinocytes. Br J Dermatol, 2005; 152:474–480.
58.
PikułaM, ŻebrowskaME, Pobłocka-OlechL, Krauze-BaranowskaM, SznitowskaM, TrzonkowskiP. Effect of enoxaparin and onion extract on human skin fibroblast cell line—therapeutic implications for the treatment of keloids. Pharm Biol, 2014; 52:262–267.
59.
LauK, PausR, TiedeS, DayP, BayatA. Exploring the role of stem cells in cutaneous wound healing. Exp Dermatol, 2009; 18:921–933.
AuxenfansC, LequeuxC, PerruselE, MojallalA, KinikogluB, DamourO. Adipose-derived stem cells (ASCs) as a source of endothelial cells in the reconstruction of endothelialized skin equivalents. J Tissue Eng Regen Med, 2012; 6:512–518.
62.
DuY, RohDS, FunderburghML, et al.Adipose-derived stem cells differentiate to keratocytes in vitro. Mol Vis, 2010; 16:2680–2689.
63.
SchumacherA, CichorekM, PikułaM. Adipose-derived stem cells for tissue engineering and therapy of non-healing wounds. Postepy Hig Med Dosw, 2018; 72:806–821.
64.
Barańska-RybakW, PikulaM, DawgulM, KamyszW, TrzonkowskiP, RoszkiewiczJ. Safety profile of antimicrobial peptides: camel, citropin, protegrin, temporin a and lipopeptide on HaCaT keratinocytes. Acta Pol Pharm, 2013; 70:795–801.
65.
PikułaM, SmużyńskaM, KrzystyniakA, et al.Cystatin C peptidomimetic derivative with antimicrobial properties as a potential compound against wound infections. Bioorg Med Chem, 2017; 25:1431–1439.
66.
ParkSA, RaghunathanVK, ShahNM, et al.PDGF-BB does not accelerate healing in diabetic mice with splinted skin wounds. PLoS One, 2014; 9:e104447.
67.
AgrenMS, SteenfosHH, DabelsteenS, HansenJB, DabelsteenE. Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent. J Invest Dermatol, 1999; 112:463–469.
68.
De DonatisA, ComitoG, BuricchiF, et al.Proliferation versus migration in platelet-derived growth factor signaling. J Biol Chem, 2008; 283:19948–19956.
WadhwaM, BirdC, DilgerP, Gaines-DasR, ThorpeR. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J Immunol Methods, 2003; 278:1–17.
71.
ShankarG, ShoresE, WagnerC, Mire-SluisA. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol, 2006; 24:274–280.
72.
KhatoonZ, FiglerB, ZhangH, ChengF. Introduction to RNA-Seq and its applications to drug discovery and development. Drug Dev Res, 2014; 75:324–330.
73.
FischerHP, HeyseS. From targets to leads: the importance of advanced data analysis for decision support in drug discovery. Curr Opin Drug Discov Devel, 2005; 8:334–346.
74.
KrishnaswamyVR, MintzD, SagiI. Matrix metalloproteinases: the sculptors of chronic cutaneous wounds. Biochim Biophys Acta Mol Cell Res, 2017; 1864:2220–2227.
75.
ZomerHD, TrentinAG. Skin wound healing in humans and mice: challenges in translational research. J Dermatol Sci, 2018; 90:3–12.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
